Yahoo Αναζήτηση Διαδυκτίου

Αποτελέσματα Αναζήτησης

  1. 3 Σεπ 2024 · Loading dose: 15 mg/kg infused intravenously over 30 to 60 minutes; monitor ECG and blood pressure; stop the infusion if hypotension occurs or QRS complex widens by more than 50% of baseline. Renal Dose Adjustments. Oral: CrCl less than 10 mL/min: A dosing interval of every 8 to 24 hours is recommended.

  2. 8 Μαΐ 2023 · Procainamide is given IV or PO with the onset of action in 10 to 30 minutes. The loading dose is of IV procainamide is 10 to 17 mg/kg and administered at a rate of 20 to 50 mg/min. Alternatively, this may be dosed at 100 mg every 5 minutes in adult patients.

  3. www.aclsonline.us › drugs › procainamideProcainamide in ACLS

    For monomorphic ventricular tachycardia with a pulse or polymorphic ventricular tachycardia with a pulse (not due to torsades de pointes), administer procainamide at 1-2 grams over 5-60 minutes. See the dosage table above for further details.

  4. The mean dose of procainamide was 1207 ± 487 mg/day. Procainamide therapy significantly decreased ICD interventions (median 5 [0–22.5] vs 15.5 [3–32.25], P < .05). Procainamide also decreased the total number of VT/VF episodes (median 5.5 [0.75–30] vs 19 [7.5–30], P < .05). Only 3 patients (8.8%) presented severe side effects (dyspnea ...

  5. Antiarrhythmic infusions for stable wide-QRS tachycardia procainamide IV dose: 20–50 mg/min until arrhythmia suppressed, hypotension ensues, QRS duration increases > 50% or maximum dose 17 mg/kg given. Maintenance infusion: 1–4 mg/min. Avoid if prolonged QT or CHF. First dose: 150 mg over 10 minutes. Repeat as needed if VT recurs.

  6. procainamide might represent an alternative strategy for pre-venting the recurrence of ventricular tachyarrhythmias and ICD discharges. Procainamide is a class 1a antiarrhythmic agent whose primary mechanism is related to its antagonism of cardiac sodium channels delaying phase 0 of the cardiac cycle. Procainamide and its metabolite N-acetyl ...

  7. Procainamide was more effective by 1.5 hours in those with AF than AFL/both: 46.3% vs 22.2% (P<0.01). All predictors except dose were associated with higher adjusted odds of cardioversion by 1.5 hours (Table).